NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer
Abstract Trastuzumab serves as a cornerstone of first-line therapy for HER2-positive (HER2+) breast cancer; however, a significant challenge arises due to the emergence of resistance within approximately one year of commencement of treatment, particularly in advanced cases with metastatic disease wh...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-02-01
|
| Col·lecció: | Cell Communication and Signaling |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12964-024-02023-9 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|